| Name | Title | Contact Details |
|---|
We are a full-service agency providing insurance in personal, business, bonding, farm, life, and flood. Our staff has over 400 years of experience. We pride ourselves on customer service and knowledge of the products we offer. Stop in to one of our North Dakota or Minnesota locations.
WE ARE A DESIGN COMPANY. Allovus is a woman-owned equal opportunity employer committed to fostering an inclusive and creative environment. Our employees produce meaningful work, create strong community connections, and inspire delight in our clients. Studio Our skilled and collaborative Design Studio team provides beautiful, elegant, and functional solutions for our clients. No matter the creative challenge, our intentionally small and agile team operates as a one-stop design shop. Custom Solutions Deliverable based teams, managed for you. In todays world, many of our clients are looking for ways to augment their own teams with creative talent in different ways outside the typical individual contractor approach. Our ability to build, nurture, and employ teams of people is one of our strongest attributes as an organization. Were excited to provide a model to our clients which allows you to retain a world-class team, while meeting the compliance standards of your organization, all while delivering amazing designs on time and on budget. Search We specialize in permanent placement using a holistic, qualitative approach to make the perfect match.
The New York Jets are a professional football team headquartered in Florham Park, New Jersey, representing the New York metropolitan area. It is a privately owned business with under 200 employees. Founded more than 50 years ago, the Jets franchise has defined itself as a trailblazer, trendsetter and leader in the regions sports landscape and across the NFL. Since Chairman and CEO Woody Johnson purchased the team in 2000, the team has undergone a major revitalization and rebranding, focused on winning both on and off the field. For Johnson, capturing the franchises second championship is priority #1. Under his ownership, the team has posted seven winning seasons, appeared in seven postseason games, including two AFC Championship Game appearances, and winning an AFC East division title in 2002. They have also made strides off the field with the opening of two state-of-the-art homes: the Atlantic Health Jets Training Center in 2008 and MetLife Stadium in 2010. Honored as one of NJ Bizs 2018 Best Places to Work in New Jersey. This award recognizes and honors New Jersey-based employers who show dedication to their employees professional growth and quality of life.
Hadron is a premier A- VIII rated international hybrid fronting carrier, dedicated to transforming the insurance landscape for SMEs and lower middle-market insureds. As a modern market entrant, Hadron boasts a robust backing of $250 million in capital, and a strategic partnership network within the Altamont family. Hadron is an unencumbered, clean insurance entity specializing in custom insurance solutions for todays risk landscape. Our commitment to excellence is demonstrated in our top-tier operational frameworks and cutting-edge technology built to exceed expectations of partners and clients.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.